|View printer-friendly version|
|Illumina Announces the iHope Network, an Expansion of Its iHope Philanthropic Clinical Whole Genome Sequencing Program|
iHope Network Members Include Illumina, GeneDx, Genome.One, and HudsonAlpha; Dedicated to Help Find Answers for Underserved Families with Children Facing Rare and Undiagnosed Diseases
Through whole-genome sequencing – the process of determining the genetic code or instructions in the cells within a person’s body – the iHope Network and their respective clinical partners strive to end years-long diagnostic odysseys. These odysseys average seven years in length and include multiple inconclusive tests, surgeries and procedures, many of which do not result in answers or treatment options for these children and their families.
The iHope Network members have committed to a minimum philanthropic donation of 10 whole genome tests per year (10 patients). Additionally, iHope Network organizations have agreed to donate the variants identified through iHope to public databases, like Clinvar, which are freely accessible, public archives of reports of the relationships among human variations and their related symptoms or diseases. By doing so, the public wealth of knowledge will continue to grow and provide benefit to many more patients who depend on the precision of genomic medicine.
With precision medicine and large-scale genomic initiatives being launched across the globe, genomics is reaching an inflection point in public awareness. The iHope program aims to build on that public awareness by demonstrating how next-generation sequencing can create a significant impact – by helping undiagnosed patients and their families find long sought-after answers.
“We are delighted to become a participating partner of Illumina’s iHope
“We’ve seen firsthand how a diagnosis can help families get a clearer
understanding of the journey ahead,” said
“The evidence is clear that genomic medicine can directly benefit
patients. And there are millions of patients who need whole-genome
sequencing today, and who cannot afford it,” said Howard J.
Jacob, Ph.D., Executive Vice President for Genomic Medicine and Chief
Genomic Medicine Officer,
The ultimate goal of the iHope Network is to increase awareness and adoption of cWGS and demonstrate to the community that clinical whole genomes are a needed resource for all pediatric patients facing rare and undiagnosed diseases. An iHope Network Summit will take place later this year. To learn more about the program or to become part of the iHope Network, please visit: www.illumina.com/ihope.
GeneDx is a world leader in Genomics with an acknowledged expertise in
rare and ultra rare genetic disorders, as well as one of the broadest
menus of sequencing services available among commercial laboratories.
GeneDx provides testing to patients and their families in more than 55
countries. GeneDx is a business unit of
About Genome.One and the
Genome.One (www.genome.one) is
a pioneering health information company providing genetic answers to
life’s biggest health questions through clinical Whole Genome
Sequencing. Genome.One aims to enhance the lives of patients, families
and communities across the world. Genome.One is a wholly owned
subsidiary of the
About Illumina, Inc.